Company Filing History:
Years Active: 1985-2011
Title: Edgar L Milford: Innovator in T-Cell Membrane Protein Research
Introduction
Edgar L Milford is a notable inventor based in Dover, MA (US). He has made significant contributions to the field of immunology, particularly through his research on T-cell membrane proteins. With a total of 3 patents, Milford's work has the potential to impact various medical applications.
Latest Patents
Milford's latest patents focus on the T-cell membrane protein known as TIRC7. This invention describes a T-cell immune response cDNA 7 (TIRC7) that encodes a novel T-cell transmembrane protein. The patents detail peptides and polypeptides derived from TIRC7, as well as antibodies that recognize these (poly)peptides. Notably, the inventions include methods for inhibiting T-cell stimulation through the TIRC7 protein. Furthermore, the patents cover vectors containing polynucleotides and host cells transformed with these vectors, which can be used to produce the aforementioned proteins, peptides, or polypeptides. The applications of these inventions extend to pharmaceutical and diagnostic compositions, as well as methods for modulating immune responses, particularly in the context of organ transplantation and treatment of autoimmune, allergic, or infectious diseases.
Career Highlights
Throughout his career, Edgar L Milford has worked at The Brigham and Women's Hospital, Inc., where he has contributed to groundbreaking research in immunology. His work has been instrumental in advancing the understanding of T-cell responses and their modulation.
Collaborations
Milford has collaborated with notable colleagues, including Nalan Utku and Steven R Gullans. These partnerships have further enriched his research and innovation in the field.
Conclusion
Edgar L Milford's contributions to the field of immunology through his patents on T-cell membrane proteins highlight his role as an influential inventor. His work has the potential to lead to significant advancements in medical treatments and therapies.